Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

← catalyst calendar

NCT06588283

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 3

Status

Completed

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

281actual

Sites

Countries

Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-09-30

actual

When the study began enrolling

Primary completion

2026-01-08

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-06-01

actual

The whole study's end, after follow-up

First posted

2024-09-19

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Psoriasis
Obesity

Interventions

Drug: Ixekizumab — also filed as LY2439821
Drug: Tirzepatide — also filed as LY3298176

Primary outcome

what the primary-completion date above is the date OF

Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction

measured Baseline to Week 36

Publications

PMID 42139049 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed